GlaxoSmithKline (GSK) Stock Rating Reaffirmed by Shore Capital

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reaffirmed by equities researchers at Shore Capital in a research report issued to clients and investors on Friday.

GSK has been the topic of several other research reports. UBS set a GBX 1,550 ($21.41) target price on GlaxoSmithKline and gave the company a “buy” rating in a research note on Thursday, February 8th. Credit Suisse Group set a GBX 1,300 ($17.96) target price on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, February 8th. Goldman Sachs set a GBX 1,750 ($24.18) target price on GlaxoSmithKline and gave the company a “buy” rating in a research note on Friday, March 2nd. Liberum Capital restated a “buy” rating and issued a GBX 1,760 ($24.32) target price on shares of GlaxoSmithKline in a research note on Monday, January 15th. Finally, JPMorgan Chase & Co. restated a “neutral” rating and issued a GBX 1,330 ($18.38) target price on shares of GlaxoSmithKline in a research note on Wednesday, December 13th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of GBX 1,529.55 ($21.13).

GlaxoSmithKline (LON GSK) opened at GBX 1,315.60 ($18.18) on Friday. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($17.07) and a 1-year high of GBX 1,724.50 ($23.83). The firm has a market capitalization of $65,630.00 and a PE ratio of 2,482.26.

In other GlaxoSmithKline news, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were acquired at an average cost of GBX 1,278 ($17.66) per share, with a total value of £7,182.36 ($9,923.13). Also, insider Patrick Vallance sold 14,022 shares of the business’s stock in a transaction that occurred on Monday, February 19th. The stock was sold at an average price of GBX 1,318 ($18.21), for a total value of £184,809.96 ($255,332.91). In the last ninety days, insiders have acquired 591 shares of company stock worth $756,678 and have sold 23,765 shares worth $31,152,709.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline (GSK) Stock Rating Reaffirmed by Shore Capital” was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3298464/glaxosmithkline-gsk-stock-rating-reaffirmed-by-shore-capital.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Evine   Shares Down 6.4%
Evine Shares Down 6.4%
Rite Aid  Shares Up 5%
Rite Aid Shares Up 5%
Pennsylvania R.E.I.T.  Trading 5.7% Higher
Pennsylvania R.E.I.T. Trading 5.7% Higher
Slothcoin  One Day Volume Hits $4,181.00
Slothcoin One Day Volume Hits $4,181.00
YEE  Price Up 12.9% Over Last 7 Days
YEE Price Up 12.9% Over Last 7 Days
Lakeland Industries  Given Average Rating of “Strong Buy” by Brokerages
Lakeland Industries Given Average Rating of “Strong Buy” by Brokerages


© 2006-2018 Ticker Report. Google+.